Levalbuterol tartrate HFA MDI + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Exercise-induced Bronchospasm
Conditions
Exercise-induced Bronchospasm
Trial Timeline
Dec 1, 2005 → Feb 1, 2006
NCT ID
NCT00268723About Levalbuterol tartrate HFA MDI + Placebo
Levalbuterol tartrate HFA MDI + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Exercise-induced Bronchospasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00268723. Target conditions include Exercise-induced Bronchospasm.
What happened to similar drugs?
2 of 7 similar drugs in Exercise-induced Bronchospasm were approved
Approved (2) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00268723 | Phase 3 | Completed |
Competing Products
10 competing products in Exercise-induced Bronchospasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhaler | AstraZeneca | Phase 3 | 40 |
| Benralizumab | AstraZeneca | Phase 3 | 36 |
| Administration of montelukast or placebo | Merck | Pre-clinical | 18 |
| Ambrisentan | Gilead Sciences | Approved | 43 |
| Combination DSCG and Reproterol | Sanofi | Phase 2 | 35 |
| Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified) | Organon | Approved | 37 |
| Comparator: Montelukast + Comparator: Placebo | Organon | Phase 3 | 34 |
| Comparator: Montelukast + Comparator: Placebo | Organon | Phase 3 | 34 |
| montelukast sodium + Comparator: placebo (unspecified) | Organon | Phase 1 | 23 |
| Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol) | Organon | Phase 3 | 34 |